TP53 and hepatocellular carcinoma: Combined analysis of H2AFZ expression and TP53 status suggested that H2AFZhigh/TP53mut HCC patients had the worst prognosis and the greatest risk of tumor progression, while they were most likely to be sensitive to ICBs.